PLOD3 and colorectal carcinoma: Given that higher PLOD3 expression was associated with lower immunescore, infiltration of multiple immune cells and many immune-related genes, TMB, and MSI score, consistent with the higher TIDE score, we speculated that CRC patients with high PLOD3 expression may be resistant to immunotherapy, which was justified in an immunotherapy-treated cohort.